Andrew is currently the Head QPPV and Alliance Office at Grünenthal GmbH and is responsible to provide oversight to the QPPV on the global pharmacovigilance system including infrastructure, key processes, compliance metrics, safety profiles and safety risks related to Grünenthal’s medicinal products. Before joining Grünenthal, Andrew was Pharmacovigilance Manager at ProductLife Ltd. He has a master’s degree in Chemistry from York University and an Ph.D in Biochemistry from Cambridge University. About Grünenthal The Grünenthal Group is an independent, international research-based pharmaceutical family owned company with headquarters in Aachen, Germany. Building on our expertise in pain management, we are one of the last five remaining research-based pharmaceutical companies with headquarters in Germany and invest sustainably in research and development. We are intensely focused on discovering new ways to treat pain better and more effectively, with fewer side-effects than current therapies. Altogether, the Grünenthal Group has affiliates in 25 countries worldwide. Grünenthal products are sold in more than 155 countries and more than 5,000 employees are working for the Grünenthal Group worldwide. In 2014, revenues of Grünenthal achieved more than 1 Billion Euros. More information: www.grunenthal.com